Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (221-230 of 280) with videos related to

Pageof 28
Sort By:
Eclinicalmedicine|August 14, 2025
Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II studyChong Wang, Fei Kong, Haibing Gao, et al.
Virology Journal|April 18, 2019
Hepatitis C screening in hospitals: find the missing patientsLili Liu, Hongqin Xu, Yue Hu, et al.
Biomed Research International|August 19, 2014
Factors associated with spontaneous clearance of hepatitis C virus in Chinese populationFei Kong, Yu Pan, Xiumei Chi, et al.
Iscience|April 18, 2025
CT-based artificial intelligence system complementing deep learning model and radiologist for liver fibrosis stagingShuang Zheng, Wenao Ma, Lin Mu, et al.
Scientific Reports|September 2, 2017
Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencingYushen Du, Xiumei Chi, Chong Wang, et al.
Gut|August 20, 2018
Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoidsYanhang Gao, Zhou Zhou, Tianyi Ren, et al.
Nature Communications|October 12, 2023
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trialYue Hu, Haijun Li, Hong Zhang, et al.
Frontiers in Pharmacology|July 6, 2018
Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese VolunteersXiaojiao Li, Cai Liu, Xiaoxue Zhu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2025
External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based TherapyXingmei Liao, Qing Xie, Xiaoguang Dou, et al.
Journal of Medical Virology|January 19, 2023
Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis BYanhua Tang, Rong Fan, Zhixian Lan, et al.
Pageof 28

Showing results (221-230 of 280) with videos related to

Sort By:
Pageof 28
Eclinicalmedicine|August 14, 2025
Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II studyChong Wang, Fei Kong, Haibing Gao, et al.
Virology Journal|April 18, 2019
Hepatitis C screening in hospitals: find the missing patientsLili Liu, Hongqin Xu, Yue Hu, et al.
Biomed Research International|August 19, 2014
Factors associated with spontaneous clearance of hepatitis C virus in Chinese populationFei Kong, Yu Pan, Xiumei Chi, et al.
Iscience|April 18, 2025
CT-based artificial intelligence system complementing deep learning model and radiologist for liver fibrosis stagingShuang Zheng, Wenao Ma, Lin Mu, et al.
Scientific Reports|September 2, 2017
Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencingYushen Du, Xiumei Chi, Chong Wang, et al.
Gut|August 20, 2018
Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoidsYanhang Gao, Zhou Zhou, Tianyi Ren, et al.
Nature Communications|October 12, 2023
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trialYue Hu, Haijun Li, Hong Zhang, et al.
Frontiers in Pharmacology|July 6, 2018
Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese VolunteersXiaojiao Li, Cai Liu, Xiaoxue Zhu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2025
External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based TherapyXingmei Liao, Qing Xie, Xiaoguang Dou, et al.
Journal of Medical Virology|January 19, 2023
Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis BYanhua Tang, Rong Fan, Zhixian Lan, et al.
Pageof 28